Adela Taranu

Adela Taranu, Ph.D., has a strong background in medical affairs and regulatory medical writing. Adela started their career as a Master Research Intern at AP-HP, Assistance Publique - Hôpitaux de Paris in 2013. Adela then moved on to work as a Master Research Intern at Inserm, where they evaluated the impact of a mitochondrial receptor in cardioprotection. In 2014, they became a Scientific and Medical Project Manager at Inserm, where they collaborated with Servier Laboratoires to develop a pharmacogenetic study. Adela utilized whole exome sequencing to identify genes associated with response to antidepressant treatment. Adela joined Medtronic in 2017 as a Medical Scientific Writer in the Medical Affairs department. Adela later moved to NAMSA in 2019, working as a Senior Regulatory Medical Writer in Medical Affairs. Currently, Adela is employed at Wörwag Pharma GmbH & Co. KG, where they have held multiple roles within the Global Medical Affairs department, including Team Lead and Head of Global Regulatory Medical Writing and Head of Global Medical Advice & Writing. In their current position, Adela is responsible for advising on regulatory strategies, maintaining scientific and medical documents, mitigating medical/toxicological risks, and promoting innovation for market authorizations.

Adela Taranu, Ph.D. has an extensive education history with a focus on clinical research, pharmacogenetics, and bioengineering. In 2012, they obtained a Bachelor of Applied Science (B.A.Sc.) in Fondamental and Biomedical Sciences from Université Paris Cité. Adela then pursued a Master's degree in Pharmacology and Toxicology from the same institution, completing it in 2013.

In the following years, Adela pursued multiple Master's degrees at Université Paris-Saclay. From 2013 to 2014, they obtained a Master's degree in Pharmacology, Pharmacogenetics, and Pharmacokinetics. Simultaneously, they also completed a DIU (one-year university degree) in Pharmacogenomics and Personalised Medicine. In 2014, they achieved another Master's degree, this time in Epidemiological Genetics and Biomarkers.

Continuing their academic journey, Adela began their Ph.D. (Dr.rer.nat) in Clinical Research and Pharmacogenetics at Université Paris-Saclay in 2014 and completed it in 2017. During this time, they also acquired additional certifications to enhance their knowledge and expertise. These certifications include Leadership Essentials from THE BRIDGE international management consulting obtained in September 2021, Clinical Evaluation of Medical Devices According to the Literature from LNE obtained in November 2017, and Bioinformatics from Conservatoire National des Arts et Métiers obtained in September 2016.

Adela further expanded their skill set by completing a one-year Executive Education program in Leadership at HEC Paris in 2022. Additionally, they obtained various certifications such as Medical Devices: PMS & Risk Management from Cabinet WHITE-TILLET in 2017, Next Generation Sequencing Bioinformatics from Wellcome Genome Campus Advanced Courses and Scientific Conferences in 2015, Project Management from Université Paris-Saclay in 2015, TOEIC from ETS Global in 2016, and TOEFL from ETS Global in 2011.

Based on the chronological information provided, Adela Taranu, Ph.D. is a highly-educated individual with a strong background in clinical research, pharmacogenetics, and bioengineering.